BioCryst to Present at Upcoming Investor Conferences
- Wall Street regains some ground with help from easing virus fears
- Kohl's (KSS) Stock Tick Higher as Activist Investor Engine Capital Urges Board to Consider Sale
- Bitcoin (BTC) Price Remains Below $50,000 After Weekend Selloff, Analyst Expects a 'Hard Month'
- EV Rivian (RIVN) Shares Dip as Street Starts New Coverage With Mixed Ratings, Goldman Sachs and JPMorgan Initiate at Neutral Citing Lofty Valuation
- Dollar up against safe havens as risk sentiment improves on Omicron news
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following upcoming virtual investor conferences:
- 2021 Jefferies London Healthcare Conference—pre-recorded fireside chat available beginning Thursday, November 18 at 3:00 a.m. ET
- Piper Sandler 33rd Annual Virtual Healthcare Conference—pre-recorded fireside chat available beginning Monday, November 22 at 10 a.m. ET
- 4th Annual Evercore ISI HeathCONx Conference on Wednesday, December 1 at 3:05 p.m. ET
- JMP Securities Hematology and Oncology Summit on Monday, December 6 at 1:00 p.m. ET
Links to the live audio webcast of the Evercore and JMP presentations, and replays of all presentations, may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Arab Emirates and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
Investors:John Bluth+1 919 859 firstname.lastname@example.org
Media:Catherine Collier Kyroulis+1 917 886 email@example.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Bank Completes Acquisition of Two Former OceanFirst Branch Locations Strengthening its Central New Jersey Presence
- Innospec Appoints Leslie J. Parrette as Non-Employee Director
- Root, Inc. to Participate in the KBW Innovation in Finance Conference
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!